Tatiana Prowell: The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology.

Tatiana Prowell, Breast Cancer Scientific Lead at Office of Hematology & Oncology Products, US Food & Drug Administration, made the following post on Twitter:

“The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology. Honored to have been a part of this working group. No paywall. Regulatory Drug development.”

For details click here.
Source: Tatiana Prowell/Twitter